Galectin-3 immunodetection in follicular thyroid neoplasms: a prospective study on fine-needle aspiration samples

[1]  A. Bartolazzi,et al.  Galectin‐3 does not reliably distinguish benign from malignant thyroid neoplasms , 2006, Histopathology.

[2]  H. Gharib,et al.  Continuing Controversies in the Management of Thyroid Nodules , 2005, Annals of Internal Medicine.

[3]  L. Mills,et al.  Galectin‐3 is not useful in thyroid FNA , 2005, Cytopathology : official journal of the British Society for Clinical Cytology.

[4]  C. Lombardi,et al.  Immunocytochemical evaluation of thyroid neoplasms on thin‐layer smears from fine‐needle aspiration biopsies , 2005, Cancer.

[5]  J. Sulkes,et al.  Diagnostic value of galectin‐3 as a marker for malignancy in follicular patterned thyroid lesions , 2004, Head & neck.

[6]  V. Castronovo,et al.  Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3 , 2004, Oncogene.

[7]  Y. Takenaka,et al.  Galectin-3, a Novel Binding Partner of β-Catenin , 2004, Cancer Research.

[8]  T. Fahey,et al.  0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(7):3214–3223 Printed in U.S.A. Copyright © 2004 by The Endocrine Society doi: 10.1210/jc.2003-031811 Molecular Profiling Distinguishes Papillary Carcinoma , 2022 .

[9]  G. Winkler,et al.  The investigation of galectin-3 in diseases of the thyroid gland. , 2003, European journal of endocrinology.

[10]  Isabelle Camby,et al.  Galectins and cancer. , 2002, Biochimica et biophysica acta.

[11]  Z. Baloch,et al.  Immunohistochemical expression of galectin-3 in benign and malignant thyroid lesions. , 2002, Archives of pathology & laboratory medicine.

[12]  F. Negro,et al.  Galectin‐3, a marker of well‐differentiated thyroid carcinoma, is expressed in thyroid nodules with cytological atypia , 2002, Histopathology.

[13]  P. De Giuli,et al.  Galectin-3 as a presurgical immunocytodiagnostic marker of minimally invasive follicular thyroid carcinoma. , 2001, The Journal of clinical endocrinology and metabolism.

[14]  A. Belfiore,et al.  Fine-needle aspiration biopsy of the thyroid. , 2001, Endocrinology and metabolism clinics of North America.

[15]  A. Vecchione,et al.  Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions , 2001, The Lancet.

[16]  T. Yoshii,et al.  Expression of cytoplasmic galectin-3 as a prognostic marker in tongue carcinoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  赤埴 詩朗.  Galectin-3 : a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family , 2000 .

[18]  J. Ochieng,et al.  Galectin‐3 regulates the adhesive interaction between breast carcinoma cells and elastin , 1999, Journal of cellular biochemistry.

[19]  H. Inohara,et al.  Galectin-3 stimulates cell proliferation. , 1998, Experimental cell research.

[20]  P. De Giuli,et al.  Galectin-3 is a presurgical marker of human thyroid carcinoma. , 1998, Cancer research.

[21]  M. Sack,et al.  Fine-needle aspiration of thyroid: an institutional experience. , 1998, Thyroid : official journal of the American Thyroid Association.

[22]  H. Inohara,et al.  Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. , 1997, Cancer Research.

[23]  M. Sack,et al.  HBME-1 immunostaining in thyroid fine-needle aspirations: a useful marker in the diagnosis of carcinoma. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[24]  H. Inohara,et al.  Interactions between galectin-3 and Mac-2-binding protein mediate cell-cell adhesion. , 1996, Cancer research.

[25]  L. Trusolino,et al.  Changes in integrin and E-cadherin expression in neoplastic versus normal thyroid tissue. , 1996, Journal of the National Cancer Institute.

[26]  M. Santoro,et al.  Description of a human papillary thyroid carcinoma cell line. Morphologic study and expression of tumoral markers , 1994, Cancer.

[27]  S. Sato,et al.  Regulation of secretion and surface expression of Mac-2, a galactoside-binding protein of macrophages. , 1994, The Journal of biological chemistry.

[28]  Edward A. Lee,et al.  Decreased expression of Mac-2 (carbohydrate binding protein 35) and loss of its nuclear localization are associated with the neoplastic progression of colon carcinoma. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[29]  E. Staren,et al.  Fine-needle aspiration biopsy of the thyroid. Diagnostic accuracy when performing a moderate number of such procedures. , 1989, Archives of internal medicine.

[30]  H. Nagaraja,et al.  Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors , 2005, Modern Pathology.

[31]  Y. Takenaka,et al.  Galectin-3 and metastasis , 2004, Glycoconjugate Journal.

[32]  A. Longatto-Filho,et al.  Differential reactivity for galectin-3 in Hürthle cell adenomas and carcinomas , 2001, Endocrine pathology.

[33]  V. Castronovo,et al.  Alteration of the cytoplasmic/nuclear expression pattern of galectin-3 correlates with prostate carcinoma progression. , 2000, International journal of cancer.